ImmunoCellular Therapeutics (IMUC) Provides Update on Enrollment for Phase II Clinical Trial of ICT-107

ImmunoCellular Therapeutics Ltd (OTC: IMUC) is a Los Angeles-based, clinical-stage biotechnology company, focusing on developing new immune-based products to diagnose and treat cancer. During yesterday’s trading session, shares of IMUC opened at $2.34 and closed out at $2.28 with a slight loss of 2.56% and a large trading volume of 987 thousand as compared to [...]